DDI Effectiveness and Clinical Awareness (DECART)

Qure Healthcare

Status: Completed

Conditions: Drug-Drug Interactions

Treatments: Diagnostic Test: DDI Test Report

Study type: Interventional

Funder types: Industry

Identifiers

NCT03581994

Pro00024720

Details and patient eligibility

About

The DECART study will determine if primary care physicians, including internists and family physicians, are able to identify and address drug-drug interactions among simulated patients and whether those physicians, when given access to Aegis Drug-Drug Interaction test results, improve patient management, take steps to reduce DDI risk, and optimize unnecessary resource utilization.

Full description

The DECART study is a pre-post, two round, randomized controlled study of a nationally representative sample of 330 primary care physicians randomly assigned to a control or one of two intervention arms. Once eligibility is determined and providers are enrolled in the study, they will be asked to complete a questionnaire describing their practice and professional background. They will then care for a total of 6 CPV® simulated patients. The simulated patients will be adults aged 30-75 and present with various clinical conditions and potential drug interactions. The design and intervention consists of two rounds with an intervention among two thirds of the participants.

• Round 1 (Baseline Assessment): Providers in both the control and intervention groups will care for 3 CPV simulated patients using their standard practice approach, to evaluate their awareness of DDI interactions and associated variability in caring for patients at risk for DDIs.
• Intervention/DD! Education: Approximately 3 weeks after CPV Round 1 is complete, the intervention arms will receive Aegis test education materials, consisting of: 1) on-demand, online video on the Aegis DDI test, 2) example test results, 3) example case study, 4) clinical care reference guide, and 5) test overview.
• Round 2 (Post-Educational Intervention Assessment): Approximately 3 weeks after the intervention, all providers in the control and intervention arms will receive another 3 simulated patients to care for to determine if their awareness has changed and if their practice has improved. In the post--educational assessment, one-half of intervention participants will have access to Aegis DDI test results for their patients to help guide their decision making. The other half will have the option of receiving test results if ordered. Control physicians will continue to their standard practice approach.

Enrollment: 330 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Provide consent to participate in the study
2. Board-certified physician currently practicing in the following areas:
3. Internal medicine
4. Family medicine
5. Have practiced as a board-certified physician in internal or family medicine for greater than 2 but less than 30 years.
6. Have not used Aegis DDI
7. English-speaking
8. Community/ non-academic based practice setting
9. 40 patients under care weekly
10. 15% of their patient panel on opioid pain medications
11. Access to the internet

Exclusion criteria

1. Provide consent to participate in the study
2. Board-certified physician currently practicing in the following areas:
3. Internal medicine
4. Family medicine
5. Have practiced as a board-certified physician in internal or family medicine for greater than 2 but less than 30 years.
6. Have not used Aegis DDI
7. English-speaking
8. Community/ non-academic based practice setting
9. 40 patients under care weekly
10. 15% of their patient panel on opioid pain medications
11. Access to the internet

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

330 participants in 3 patient groups

Standard Practice

No Intervention group

Description:

Not receiving any intervention/educational materials on drug-drug interaction testing

Compulsory DDI Testing

Experimental group

Description:

Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.

Treatment:

Diagnostic Test: DDI Test Report

Optional DDI Testing

Experimental group

Description:

Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.

Treatment:

Diagnostic Test: DDI Test Report